Brad is an entrepreneur, inventor, and pharmaceutical business executive with over 30 years of experience across all aspects of pharmaceutical research, development, manufacturing, regulation, financing, and commercialization. After a long career in large pharmaceutical organizations, including running the blockbuster drugs LATUDA and LUNESTA, Brad founded his first company, Tremeau Pharmaceuticals, in 2016. Brad raised $110 million to fund Tremeau with backing from Biogen CEO Chris Viehbacher and the Swiss billionaire Ernesto Bertarelli and led the organization as CEO from concept through late-stage development. Brad founded his second company, Lennham Pharmaceuticals, in 2019 and has developed several potential promising products, including a novel form of testosterone that may have applicability in gender affirming care.

Brad helped found RIGT in early 2023 after recognizing the significant unmet medical and social need faced by gender diverse individuals, and to support a close family member who is nonbinary.

“The clinical treatment of gender diverse individuals is stigmatized and under-researched and there are no FDA-approved treatments for gender dysphoria. I helped found RIGT to do something about that.”

Brad holds an honors Bachelors of Science in Chemical Engineering from Purdue University, an MBA, cum laude, from the Stern School of Business at New York University and is an inventor on 16 issued US patents. To learn more about Brad see his recent interview in Pharmaceutical Executive here.